AIM To improve the treatment efficacy of anti tumor drug mitoxantrone, the conjugation of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies were prepared. METHODS Mitoxantrone loaded nanospheres ...AIM To improve the treatment efficacy of anti tumor drug mitoxantrone, the conjugation of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies were prepared. METHODS Mitoxantrone loaded nanospheres were prepared with emulsion heating solidification technique. A heterobifunctional reagent, N succinimidyl 3 (2 pyridyldithio) propionate (SPDP), was used as the crosslinker of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies; pharmaceutical properties of immunonanocapsuls were studied; the conjugates of nanospheres and monoclonal antibodies was confirmed with immunological methods such as slide agglutination test, fluorescent immunossay and rosset formation test, fluorescent staining and scanning electron microscope. RESULTS Mitoxantrone loaded nanospheres were spherical, with smooth surface and median diameter of 0 665 micron. When stored at 3-5, 20-25 and 37℃, RH 75% for three months, the appearance, morphology, size distribution, drug loading and in vitro release characteristics showed no significant change and the stability was satisfactory. The size analysis demonstrated that there was no obvious increase in the particle size of nanoparticles after conjugation. Immunological tests indicate highly selective binding of antibody targeted nanospheres to C erbB 2 overexpressing cells SK BR 3. CONCLUSION The conjugation of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies can keep the activity of anti C erbB 2 and increase the therapeutic efficacy of anti mammary cancer drugs.展开更多
利用BLF抗原免疫BALB/c小鼠,采用常规细胞融合技术制备了6株抗BLF的单克隆抗体细胞株,并用此抗原免疫新西兰大白兔获得了55 m L的兔多抗血清。针对腹水单抗及多抗血清进行了一系列特性分析,结果显示,5株抗体效价基本上在1∶10^6以上;间...利用BLF抗原免疫BALB/c小鼠,采用常规细胞融合技术制备了6株抗BLF的单克隆抗体细胞株,并用此抗原免疫新西兰大白兔获得了55 m L的兔多抗血清。针对腹水单抗及多抗血清进行了一系列特性分析,结果显示,5株抗体效价基本上在1∶10^6以上;间接ELISA测定6株抗体与酪蛋白、乳白蛋白和β-乳球蛋白基本无交叉反应,抗体特异性良好;抗体为IgG1亚类,2B12抗体亲和力优于其他抗体。多抗血清效价可达到1∶10^7以上,抗体也具有一定的特异性。展开更多
文摘AIM To improve the treatment efficacy of anti tumor drug mitoxantrone, the conjugation of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies were prepared. METHODS Mitoxantrone loaded nanospheres were prepared with emulsion heating solidification technique. A heterobifunctional reagent, N succinimidyl 3 (2 pyridyldithio) propionate (SPDP), was used as the crosslinker of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies; pharmaceutical properties of immunonanocapsuls were studied; the conjugates of nanospheres and monoclonal antibodies was confirmed with immunological methods such as slide agglutination test, fluorescent immunossay and rosset formation test, fluorescent staining and scanning electron microscope. RESULTS Mitoxantrone loaded nanospheres were spherical, with smooth surface and median diameter of 0 665 micron. When stored at 3-5, 20-25 and 37℃, RH 75% for three months, the appearance, morphology, size distribution, drug loading and in vitro release characteristics showed no significant change and the stability was satisfactory. The size analysis demonstrated that there was no obvious increase in the particle size of nanoparticles after conjugation. Immunological tests indicate highly selective binding of antibody targeted nanospheres to C erbB 2 overexpressing cells SK BR 3. CONCLUSION The conjugation of mitoxantrone loaded nanospheres and anti C erbB 2 monoclonal antibodies can keep the activity of anti C erbB 2 and increase the therapeutic efficacy of anti mammary cancer drugs.
文摘利用BLF抗原免疫BALB/c小鼠,采用常规细胞融合技术制备了6株抗BLF的单克隆抗体细胞株,并用此抗原免疫新西兰大白兔获得了55 m L的兔多抗血清。针对腹水单抗及多抗血清进行了一系列特性分析,结果显示,5株抗体效价基本上在1∶10^6以上;间接ELISA测定6株抗体与酪蛋白、乳白蛋白和β-乳球蛋白基本无交叉反应,抗体特异性良好;抗体为IgG1亚类,2B12抗体亲和力优于其他抗体。多抗血清效价可达到1∶10^7以上,抗体也具有一定的特异性。
